IgGA: A “Cross-Isotype” Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector Functions  by Kelton, William et al.
Chemistry & Biology
Brief CommunicationIgGA: A ‘‘Cross-Isotype’’ Engineered Human Fc
Antibody Domain that Displays Both IgG-like
and IgA-like Effector Functions
William Kelton,1 Nishant Mehta,2 Wissam Charab,1 Jiwon Lee,1 Chang-han Lee,1 Takaaki Kojima,5 Tae Hyun Kang,2
and George Georgiou1,2,3,4,*
1Department of Chemical Engineering
2Department of Biomedical Engineering
3Section of Molecular Genetics and Microbiology
4Institute for Cellular and Molecular Biology
University of Texas at Austin, Austin, TX 78712, USA
5Laboratory of Molecular Biotechnology, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya
464-8601, Japan
*Correspondence: gg@che.utexas.edu
http://dx.doi.org/10.1016/j.chembiol.2014.10.017SUMMARY
All clinically approved antibodies are of the IgG iso-
type and mediate the clearance of target cells via
binding to Fcg receptors and complement (C1q).
Even though IgA can elicit powerful cytotoxic action
via FcaRI receptor binding, IgA antibodies have not
been amenable to therapeutic development. Here,
we report the engineering of a ‘‘cross-isotype’’ anti-
body, IgGA, which combines the effector functions
of both IgG and IgA. IgGA binds to FcaRI with an af-
finity comparable to that of IgA, and to the activating
Fcg receptors, FcgRI and FcgRIIa, with high affinity,
and displays increased binding to C1q compared to
IgG. Unlike trastuzumab-IgG, trastuzumab-IgGA
potently activates both neutrophils and macro-
phages to kill Her2+ cancer cells. Furthermore, IgGA
mediates greater complement-dependent cytotox-
icity than IgG1 or IgA antibodies. The multitude of
IgGA effector functions could be important for thera-
peutic purposes and highlights the concept of engi-
neering antibodies that combine effector functions
from multiple antibody isotypes.
INTRODUCTION
Extensive clinical and laboratory evidence has demonstrated
that immune effector cytotoxic mechanisms (antibody-depen-
dent cell cytotoxicity [ADCC], antibody-dependent cell phagocy-
tosis [ADCP], and complement-dependent cytotoxicity [CDC])
play a crucial role in the clearance of cancer cells by therapeutic
antibodies (Hogarth and Pietersz, 2012). Immunoglobulin (Ig)G
immune complexes bind to the activating Fcg receptors (FcgRs),
FcgRI (CD64), FcgRIIa (CD32a), and FcgRIIIa (CD16a) that are
expressed at varying levels on leukocyte subsets (Bruhns
et al., 2009), triggering phosphorylation of the intracellular immu-
noreceptor tyrosine-based activating motif (ITAM) and, in turn,Chemistry & Biology 21, 1603–160downstream signaling events that ultimately result in the
destruction of pathogens by ADCC and ADCP. Most leukocytes
also express the inhibitory receptor FcgRIIb that signals through
an immunoreceptor tyrosine-based inhibitory motif (ITIM) to
induce anti-inflammatory responses. It has been proposed that
the ratio of binding affinity to the activating FcgRs relative to
FcgRIIb (referred to as the activation to inhibition ratio), dictates
whether stimulation with immune complexes will trigger inflam-
matory or anti-inflammatory responses (Nimmerjahn and Rav-
etch, 2012).
The pharmaceutical industry has invested heavily in the engi-
neering of antibodies that display higher affinity or binding selec-
tivity for FcgRand, thus, confer enhanced killing of target cells by
ADCC, ADCP, and/or CDC. At present, there are >15 Fc-engi-
neered antibody therapeutics in clinical trials (phase II or III)
and two that have been approved as cancer drugs: obinutuzu-
mab/Gazyva (anti-CD20) and mogamulizumab/Poteligeo (anti-
CCR4) (Beck and Reichert, 2012; Desjarlais and Lazar, 2011).
Improvements to the binding affinity, or selectivity, of antibodies
for FcgRs have been accomplished either through protein engi-
neering or through glycoengineering via the modification of the
critical glycan appended to residue N297 of the IgG Fc domain
(Desjarlais and Lazar, 2011; Nimmerjahn and Ravetch, 2012).
Examples of engineered Fc domains displaying two or more or-
ders of magnitude improvement in FcgR binding affinity or selec-
tivity have been reported (Chu et al., 2008; Jung et al., 2013).
Currently, all antibody therapeutics are of the IgG isotype
(predominantly IgG1), which is the most abundant antibody iso-
type in human serum. These IgG antibodies do not recognize the
FcaRI receptor (CD89) thatmediates the effector functions of IgA
(both for IgA1 and IgA2), the second most abundant antibody
isotype in human circulation and the most prevalent in mucosal
secretions (Woof and Kerr, 2006). FcaRI is constitutively
expressed on many cells of the myeloid lineage, such as neutro-
phils, macrophages, Kuppfer cells, and eosinophils (van Eg-
mond et al., 1999). Recent studies have clearly demonstrated
that engagement of FcaRI by IgA can elicit effective clearance
of tumor cells in vitro (Lohse et al., 2012) and in animal models
(Boross et al., 2013). This has been shown to occur via
macrophage-mediated ADCP and via ADCC by neutrophils. In9, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1603
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has been reported to be far more effective at tumor cell killing
than FcgR-mediated activation by IgG antibodies (Dechant
et al., 2007).
The ability to capitalize on neutrophils for the elimination of
pathogenic cells, especially in cancer therapy, is particularly
exciting because neutrophils constitute themost abundant leuko-
cyte subset in blood and can infiltratemany solid tumors (Gregory
and Houghton, 2011). Unfortunately, the use of IgA antibodies
as therapeutics has been hampered by several limitations. (1)
The hinge region of IgA is heavily glycosylated, and producing
proteins with multiple complex glycans can be problematic for
bioprocessing and quality control during drug development
(Woof andKerr, 2006). (2) IgA does not bind toC1q; thus, it cannot
mediate CDC through the classical complement pathway (van
Egmond et al., 2001). (3) IgA also does not bind to Fcg receptors
and, hence, cannot take advantage of the diverse mechanisms
for immune cell activation that are pertinent to IgG1 therapeutics.
(4) IgA exhibits a shorter circulation half-life than IgG because of a
lack of binding to the FcRn receptor, which is important for intra-
cellular recycling.
Here, we used a semirational protein engineering strategy to
develop a human ‘‘cross-isotype’’ Fc domain, termed IgGA,
that displays many of the immunobiological functions of both
IgA and IgG isotype antibodies. Not only do engineered IgGA an-
tibodies bind to human FcaRI with an affinity similar to that of IgA
antibodies, they also display binding to human FcgRI, FcgRIIa/b,
and C1q with an affinity similar to that of IgG1 antibodies. With
human neutrophils as effector cells, trastuzumab-IgGA displays
much higher ADCC activity compared to clinical-grade trastuzu-
mab (IgG) and ADCC activity comparable to that of trastuzumab
formatted as an IgA. Furthermore, trastuzumab-IgGA was much
more potent than its IgG counterpart in eliciting phagocytosis
(ADCP) of MDA-MB-453 breast cancer cells, which express
moderate levels of Her2. Additionally, unlike IgA, which can acti-
vate complement only weakly via the alternative and lectin-medi-
ated pathways (Roos et al., 2001), we show that IgGA is at least
as effective as IgG1 in mediating CDC.
RESULTS AND DISCUSSION
The FcaRI-binding site of the IgA1 Fca domain is composed of
residues in the AB helix/loop of the CHa12 domain and multiple
regions within CHa13 (crystal structure, Protein Data Bank
[PDB] ID: 1OW0) (Herr et al., 2003a). We used Ala scanning
mutagenesis to identify the relative importance of FcaRI contact
residues within the a1 loop of CHa12 (L257, L258), ‘‘noncontact’’
residues within the crystallographically poorly resolved a2 loop
of CHa12 (E313, N316, and H317), and certain contacting resi-
dues within 4 A˚ of FcaRI in the CHa13 domain: R382 (C strand),
E389 (CC0 loop), M433 (F strand), E437 (FG loop), L441 (FG loop),
and F443 (G strand) (Figures S1A and S1B available online).
Mutant Fca1 domains were expressed in human embryonic kid-
ney 293 (HEK293) cells, and binding to purified FcaRI-GST, also
produced in HEK293 cells, was determined by ELISA (Fig-
ure S1C). Consistent with earlier reports (Carayannopoulos
et al., 1996), an L-Ala substitution at L258 in the a1 loop of the
CHa12 domain was found to abrogate FcaRI binding. Further in-
spection of the Fca L258A protein by nonreducing SDS-PAGE1604 Chemistry & Biology 21, 1603–1609, December 18, 2014 ª2014revealed that this mutation markedly impacts Fca1 assembly.
In contrast, an Ala mutation of the adjacent residue (L257) had
essentially no effect on Fca1 assembly or FcaRI binding. Muta-
tion of either E313 or N316 in the a2 loop abolished FcaRI bind-
ing, possibly through the disruption of hydrogen bonding with
Y86 of FcaRI. Within the CHa13 domain, charged residues in
the C beta sheet (R382 and E389) were moderately important
for binding, while M433, which lies within a hydrophobic binding
pocket, was essential for FcaRI binding. However, other resi-
dues within the hydrophobic binding pocket (E437, L441, and
F443) were more tolerant of Ala substitution.
Fc domains comprising the CHa13 fused to CHg12 do not bind
to FcaRI (Chintalacharuvu et al., 2001). We constructed a series
of chimeric Fc domains using this CHg12-CHa13 fusion as a tem-
plate in order to preserve important CC0 loop, F strand, FG loop,
andG strand contacts identified in the cocrystal structure and by
Ala scanning. Because the CHg13 domain is not directly involved
in binding to the FcgRs, we reasoned that exchange of this
domain would have a minimal effect on FcgR affinity. Both the
a2 loop and parts of the a1 loop of CHg12 were exchanged
with the respective sequences from CHa12, since these two
loops are also important for binding to the receptor, as shown
earlier. One construct, which we termed IgGA (Figures 1A and
1B), had a1 loop residues 245–258 (PKPKDTLMISRTPE) of
CHg12 and 340–447 (KGQPR. LSPGK) of CHg13 replaced
with CHa12 residues 251–263 (PALEDLLLGSEAN) and CHa13
residues 341–450 (SGNTF. KTIDR). In addition, a Gly residue
was inserted following CHa12 residue 257 (to ensure that the
length of the grafted loop from CHa12 is consistent with that of
CHg12). When the IgGA Fc was expressed in HEK293 cells, it
was found to assemble efficiently and to bind to both FcaRI
and to certain FcgRs by ELISA (data not shown; see surface
plasmon resonance [SPR] analysis discussed later).
The Fab domains of trastuzumab were fused to the IgGA Fc
(trastuzumab-IgGA) or, alternatively, to Fca1 lacking the IgA tail-
piece, a C-terminal sequence required for J-chain-mediated
dimerization and transcytosis of secretory IgA across epithelial
barriers (Woof and Kerr, 2006) (deletion of residues 455–472,
PTHVN. DGTCY, antibody designated trastuzumab-IgA). Tras-
tuzumab-IgGA could be expressed at a high yield and showed
>90% correct assembly into the dimeric form, compared to
40% for trastuzumab-IgA (Figure 1C). Both glycan crowding
and the deletion of the tailpiece have been previously shown to
result in poor assembly of intrachain disulfide bonds in the hinge
region of monomeric IgA1 (Atkin et al., 1996; Mattu et al., 1998),
accounting for the poor assembly of trastuzumab-IgA that we
observed. We also expressed and purified trastuzumab (an
IgG1 antibody, designated herein as wild-type [WT] trastuzu-
mab) and trastuzumab containing an N297D substitution. The
mutation of N297 in IgG abolishes glycosylation, leading to a
loss of binding to Fcg receptors as well as C1q and, thus, dis-
playing background levels of ADCC, ADCP, and CDC.
The dissociation constants (KD) of trastuzumab-IgGA, trastu-
zumab-IgA, and clinical-grade WT trastuzumab with purified
human Fc receptors (FcgRI, FcgRIIa, FcgRIIb, and FcaRI) and
with C1q were determined by SPR analysis (Table 1; Figures
S2A and S2B). Notably, trastuzumab-IgGA bound to FcaRI
with an apparent KD of 502 nM, an affinity only slightly lower
than the value determined for binding to trastuzumab-IgAElsevier Ltd All rights reserved
Figure 1. Engineering of IgGA
(A) Sequence of the Fc domain of IgGA aligned with IgG1. Residues within the IgG1 CHg12 and CHg13 domains were exchanged with the underlined residues in
orange from IgA1 to create IgGA. The Gly insertion is shown in black.
(B) Model of IgGA structure. IgG1 residues in gray and IgA1 residues in orange (PDB ID: 3DO3 for IgG1 Fc fragment).
(C) Expression of trastuzumab-IgGA (T-IgGA), trastuzumab-IgA (T-IgA), WT trastuzumab (T-IgG), and trastuzumab-N297D lacking the Fc glycan in HEK293 cells
(T-IgG N297D). Antibodies were expressed in HEK293 cells, purified by Protein L chromatography (T-IgA, T-IgGA) or Protein A chromatography (T-IgG, T-IgG
N297D), and separated by nonreducing SDS-PAGE on a 4%–20% gel.
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2003b). In contrast to trastuzumab-IgA, which did not bind to
any FcgRs or to C1q, trastuzumab-IgGA displayed high-affinity
binding to FcgRI, FcgRIIa, and FcgRIIb. Notably, trastuzumab-
IgGA bound to FcgRI with very high affinity (KD = 0.83 nM),
only slightly lower than that of clinical-grade trastuzumab
(KD = 0.36 nM). However, we could not detect the binding of tras-
tuzumab-IgGA to FcRn or FcgRIIIa (CD16a) by ELISA, even
though, in the case of the latter, all the Fc:FcgRIIIa contact
residues observed in the cocrystal structure are preserved
(PDB ID: 3SGJ) (Ferrara et al., 2011). Thus, it appears that
conformation changes at the CH2/CH3 domain interface,
possibly caused by the replacement of CHg13 with CHa13,
may be responsible for abolishing binding to FcgRIIIa. The loss
of binding to FcgRIIIa will interfere with natural-killer-cell-medi-
ated ADCC, which is strongly implicated in the mechanism of
some clinical antibodies. Unexpectedly, trastuzumab-IgGA
bound C1q with a higher apparent affinity relative to IgG1 (tras-Chemistry & Biology 21, 1603–160tuzumab-IgGA, KD = 28 nM, compared with WT trastuzumab,
KD = 84 nM), which, as an IgG1 isotype antibody, recruits C1q
very efficiently.
IgGA Mediates Potent Cancer Cell Killing by Fca and
Fcg-Dependent Mechanisms
Neutrophils are potent immune mediators of ADCC function, ex-
pressing high levels of FcaRI, FcgRIIa, and FcgRIwhen activated
via inflammatory cytokines (Bakema et al., 2011). Even in their
immature state (intermediate CD11b, low CD16 expression),
neutrophils can kill tumor cells opsonized by IgA antibodies but
not by IgG antibodies (Otten et al., 2005). Therefore, there is
considerable interest in harnessing neutrophils for tumor cell
elimination (Pascal et al., 2012; Souto et al., 2011; van Egmond
and Bakema, 2013). ADCC assays were performed by detecting
chromium 51 (51Cr) released from Her2-overexpressing breast
cancer cells (SkBr3) following incubation with neutrophils and
antibody (Figure S3A). Neutrophils from three healthy donors9, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1605
Table 1. SPR Analysis of Fc Receptor Binding
Variant FcgRI FcgRIIa
KD (nM)
FcgRIIb FcgRIIIa FcRn C1q FcaRI
IgG 0.36 ± 0.06 1,140 ± 50 2,550 ± 140 ND ND 84 ± 10 –
IgA – – – – – ND 233 ± 11
IgGA 0.83 ± 0.16 2,020 ± 110 4,330 ± 240 – – 28 ± 7 502 ± 41
Equilibrium binding analysis was performed for trastuzumab-IgGA, trastuzumab-IgA, and WT trastuzumab (IgG1) with purified monomeric FcgRIIa,
FcgRIIb, or FcaRI. Kinetic analysis was used to determine binding affinities for the high-affinity FcgRI and C1q interactions. For all interactions, anti-
bodies were amine coupled to CM5 Biacore chips, and receptors were introduced at concentrations up to 10 mM. ND indicates that the affinity was not
determined by Biacore, whereas a dash indicates that no binding was detected by ELISA (data are presented as mean ± SD; n = 3). See also Figure S2
for sensograms.
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late the expression of FcgRI (Figure S3D). 51Cr-labeled SkBr3 tu-
mor cells were mixed with trastuzumab-IgA, trastuzumab-IgG,
trastuzumab-IgGA, or trastuzumab-IgG-N297D (as a control
for Fc independent activity) at concentrations of 0.2, 2, and
20 mg/ml. Control wells were included, lacking either antibodies
(no Ab control), or SkBr3 target cells (spontaneous release con-
trol). Wells containing lysis buffer were also included (complete
lysis control). Neutrophils were added at an 80:1 effector:tumor
cell ratio and incubated for 4 hr. We observed that trastuzumab
IgGA induced high levels of neutrophil-mediated ADCC (up to
50%) at antibody concentrations as low as 0.2 mg/ml (Figure 2A).
With neutrophils as effector cells, trastuzumab IgGA was far
more effective than IgG-formatted trastuzumab (WT trastuzu-
mab). The latter displayed essentially no cytotoxic activity and
was indistinguishable from the trastuzumab-IgG-N297D anti-
body control.
CD11b+ macrophages express high levels of FcaRI/FcgRs,
are able to infiltrate the tumor microenvironment, and eliminate
pathogenic cells primarily via phagocytosis (ADCP) (Simpson
et al., 2013). We evaluated the ability of monocyte-derived mac-
rophages—differentiated from monocytes isolated from whole
blood by incubation for 7 days with granulocyte macrophage
colony-stimulating factor (GM-CSF) cytokine—to ingest Her2-
expressing cancer cells (Figure S3B). All blood donors were gen-
otyped as homozygous for the R131 FcgRIIa allele, which has
lower affinity for IgG1 than the H131 allele and are, therefore,
less likely to mount IgG1-mediated ADCP responses as robustly
as homozygous H131 donors. In these experiments, we used
MDA-MB-453 cells expressing moderate levels of Her2 antigen,
as these cells have been reported to be resistant to elimination
by ADCP using trastuzumab in vitro (Narayan et al., 2009).
MDA-MB-453 cells were fluorescently labeled with PKH67 and
opsonized with trastuzumab-IgA, trastuzumab-IgG, or trastuzu-
mab-IgGA, each at concentrations of 0.05, 0.5, and 5 mg/ml; and
macrophages were added at a 5:1 effector:tumor cell ratio. After
2 hr of incubation, the extent of phagocytosis was evaluated
using flow cytometry by determining the percentage of cells
staining double positive for PKH67 and anti-CD11b/CD14. WT
trastuzumab was unable to mediate phagocytosis of MDA-MB-
453 over background. In contrast, IgGA was able to effectively
clear up to 50% of the tumor cells targeted (Figure 2B), a degree
of phagocytosis comparable to that observed with trastuzumab-
IgA. Consistent with these observations, a number of studies
have established that the activation of macrophages via FcaRI1606 Chemistry & Biology 21, 1603–1609, December 18, 2014 ª2014can strongly elicit ADCP of cancer cells (Keler et al., 2000; van
Egmond et al., 1999).
Unlike IgA, but similarly to IgG1, IgGA binds C1q with high af-
finity. Complement activation via the classical antibody-depen-
dent pathway is implicated as a key mechanism in the function
of type I anti-CD20 antibodies such as rituximab (Zhou et al.,
2008). After initially performing CDC assays with IgGA, IgG,
and IgA antibodies in trastuzumab format, in which we saw no
release of fluorescent dye from calcein-AM-loaded MDA-MB-
453 cells, we fused the rituximab Fab to each of these respective
Fc domains for expression in HEK293 cells. Calcein-AM-loaded
Raji cells that express high levels of CD20 were incubated with
rituximab-IgGA, rituximab-IgA, or WT rituximab (IgG1) and fresh
human serum for 1 hr, at which point the degree of release of the
dye in the supernatant was determined (Figure S3C). Trastuzu-
mab-IgG, was included as a negative control and, in addition,
the spontaneous release of the dye was measured. IgGA ex-
hibited highly potent CDC, resulting in tumor cell lysis at higher
antibody concentrations (up to 70%) and detectable killing
even at a very low concentration (0.625 mg/ml, up to 18% lysis)
(Figure 2C). Consistent with the higher affinity of IgGA for C1q
in vitro (Table 1), rituximab-IgGA was more efficient than WT rit-
uximab at lower concentrations of antibody, e.g., up to 65% lysis
compared to a maximum of 35%with rituximab at 2.5 mg/ml. We
also observed a low but repeatable degree of CDC using rituxi-
mab-IgA at the highest concentration tested. Despite a lack of
C1q binding, it has been reported that IgA can weakly activate
complement via the lectin-mediated pathway and also, indi-
rectly, recruit C1q during tumor cell apoptosis (apoptotic events
are reported to induce antibody-independent C1q deposition)
(Pascal et al., 2012). As expected, heat inactivation of the
serum prior to use in these assays abrogated all CDC activity
(Figure S3E).
SIGNIFICANCE
It is well established that engagement of the FcaRI receptor
by IgA immune complexes elicits potent ADCC by activated
neutrophils and eosinophils, as well as high phagocytic po-
tency by macrophages (Dechant and Valerius, 2001; van Eg-
mond et al., 2001). However, the challenges associated with
IgA expression and purification and its inability to capitalize
on the cytotoxic mechanisms that depend on FcgR or the
activation of the classical complement pathway have limited
the use of this antibody isotype as a therapeutic. We haveElsevier Ltd All rights reserved
Figure 2. ADCC, ADCP, and CDC Assays
(A) ADCC of 51Cr loaded SkBR-3 Her2+ cells sensitized using anti-Her2 (trastuzumab) antibody variants having different Fc domains with IFN-g activated human
neutrophils as effector cells. An 80:1 effector (neutrophil):tumor cell ratio was used, with neutrophils first activated by overnight culture with IFN-g (Otten et al.,
2005). The dashed line indicates the values for the no-antibody control.
(B) ADCP assays with monocyte-derived humanmacrophages and PKH67-labeled, Her2+medium-expressing MDA-MB-453 tumor cells (Rhodes et al., 2002) at
a 5:1 effector:tumor cell ratio. The dashed line indicates the no-antibody negative control.
(C) CDC assays with fresh human serum using rituximab antibody variants to target calcein-loaded Raji CD20+ tumor cells. Trastuzumab-IgG was used as a
negative control.
All data are presented as the mean ± SD (n = 3).
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IgGA antibody that displays high affinity to FcaRI and re-
tains binding to the activating Fcg receptors FcgRI and
FcgRIIa. Furthermore, we show that IgGA exhibits a 3-fold
lower dissociation constant with C1q as compared to
IgG1, which translates to improved CDC activity. While
IgGA does not show affinity for FcgRIIIa, nor does it bind
to FcRn in a pH-dependent manner, ongoing protein en-
gineering efforts in our lab are focused on identifying
improved IgGA variants that display the full spectrum of
Fc-binding activities desirable for therapeutic applications.
Despite this loss of binding, the combination of the robust
ADCC activity of IgGA with neutrophils, coupled with the
excellent ability of IgGA to elicit ADCP by macrophages
and its high CDC activity, are likely to present a great advan-
tage for the clearance of pathogenic cells, especially in can-Chemistry & Biology 21, 1603–160cer. In particular, the ability of IgGA to unleash the cytotoxic
potential of neutrophils is of considerable interest because
neutrophils represent the most abundant leukocyte sub-
population in blood and readily infiltrate solid tumors.
Furthermore, neutrophils can be rapidly expanded and acti-
vated to express elevated FcgRI via the administration of
granulocyte CSF (van Egmond and Bakema, 2013). Acti-
vated neutrophils have added benefits for therapy in vivo
as they secrete a multitude of cytokines and chemokines
to recruit other effector immune cell subsets (Mantovani
et al., 2011). Finally, we note that the concept of cross-iso-
type antibodies demonstrated here with the engineering of
IgGA may be extended to the creation of other types of
cross-isotype antibodies that combine effector functions
normally displayed by different isotypes, for example IgG
and IgE, for increased therapeutic potency.9, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1607
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See Supplemental Experimental Procedures for further details. Studies
involving human blood donors were performed under the oversight of the Insti-
tutional Review Board of The University of Texas at Austin (IRB# 2012-08-
0031).
SPR Affinity Measurements
IgGA, IgA, or IgG antibodies were immobilized on CM5 amine chips in pH 4.5
or 5.0 sodium acetate buffer. For equilibrium binding KD measurements,
monomeric FcgRIIa-R131, FcgRIIb, or FcaRI was passed over the chip sur-
face until equilibrium was reached. A 1:1 Langmuir isotherm model was fitted
to the data. For kinetic binding KD measurements, FcgRI or C1q was injected
onto the chip at 30 ml/min. A 1:1 Langmuir isotherm model was fitted to FcgRI
data, and a two-state reaction model was fit to the C1q data.
ADCC Assays
Neutrophils were purified from fresh human blood by Histopaque density
gradient centrifugation. After red blood cell lysis, the neutrophil fraction was
cultured overnight in RPMI medium containing 10% fetal bovine serum
(FBS) and 50 ng/ml IFN-g. Activated neutrophils were combined at an 80:1
effector:tumor cell ratio with 51Cr-labeled SkBR-3 cells and each of the trastu-
zumab variants. After 4 hr at 37C, the release of 51Cr into themediawas deter-
mined by scintillation counting.
ADCP Assays
PBMCs were purified from fresh human blood by Histopaque density gradient
centrifugation, and CD14+ monocytes were isolated by magnetic bead sepa-
ration. Monocytes were differentiated into macrophages by culture for 7 days
in RPMI medium containing 15% FBS and 50 ng/ml GM-CSF before combina-
tion at a 5:1 effector:tumor cell ratio with PKH67-labeled MDA-MB-453 cells
and each of the trastuzumab variants. After 2 hr at 37C, the cells were labeled
with anti-CD11b-APC and anti-CD14-APC. Flow cytometry was used to quan-
tify the number of phagocytosed double-positive events.
CDC Assays
Fresh human serum was mixed with each of the rituximab variants tested and
with Raji tumor cells that were loaded with calcein AM for 1 hr. Supernatants
were isolated by centrifugation and the released fluorescence was quantified
at 535 nm.
SUPPLEMENTAL INFORMATION
Supplemental Information including Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.chembiol.2014.10.017.
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